IP Library Patent Application 15391020
Patent Application
App. No. 15/391,020

PROCESS FOR MAKING RECOMBINANT ANTIDOTE TO FACTOR XA INHIBITOR

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
15/391,020
Abstract

Disclosed are methods and isolated cells useful for the improved production of function fXa derivative protein that acts as a fXa inhibitor antidote. One aspect relates to an isolated cell comprising the r-Antidote polynucleotide and Furin polynucleotide. Another aspect relates to a method for preparing the cleaved two-chain r-Antidote by expressing, in a cell, the pre-processed r-Antidote polypeptide and a Furin polypeptide.

Claims (25)

1 . An isolated cell comprising:

a first polynucleotide encoding a polypeptide comprising the amino acid sequence of SEQ ID NO: 1 or a polypeptide having at least about 80% sequence identity to SEQ ID NO: 1 and

a second non-endogenous polynucleotide encoding a polypeptide comprising the amino acid sequence of SEQ ID NO: 2 or a polypeptide having at least about 80% sequence identity to SEQ ID NO: 2.

2 . The isolated cell of claim 1 , wherein the cell is selected from the group consisting of a bacterial cell, a mammalian cell and a yeast cell.

3 . The isolated cell of claim 2 , wherein the cell is a mammalian cell.

4 . The isolated cell of claim 3 , wherein the mammalian cell is a cell-type selected from the group consisting of CHO, COS, BHK, and HEK 293.

5 . The isolated cell of claim 4 , wherein the cell-type is CHO.

6 . The isolated cell of claim 5 , wherein the cell is a CHO cell subtype selected from the group consisting of K, M and DG44.

7 . The isolated cell of claim 2 , wherein the cell is a bacterial cell.

8 . The isolated cell of claim 7 , wherein the bacterial cell is E. coli.

9 - 13 . (canceled)

14 . The isolated cell of claim 1 , wherein the first or second polynucleotide is on an extrachromosomal DNA construct.

15 . The isolated cell of claim 1 , wherein the first or second polynucleotide is on a DNA construct integrated into the chromosomal DNA of the isolated cell.

16 . The isolated cell of claim 1 , wherein the first and second polynucleotides are on one DNA plasmid.

17 . The isolated cell of claim 1 , wherein the wherein the first and second polynucleotides are on different DNA plasmids.

18 . The isolated cell of claim 1 further comprising

a first polypeptide comprising the amino acid sequence of SEQ ID NO: 1 or a polypeptide having at least about 80% sequence identity to SEQ ID NO: 1 and

a second polypeptide comprising the amino acid sequence of SEQ ID NO: 3 or a polypeptide having at least about 80% sequence identity to SEQ ID NO: 3.

19 . The isolated cell of claim 18 , wherein the ratio of the second polypeptide to the first polypeptide is at least about 8:2.

20 . The isolated cell of claim 18 , wherein the ratio of the second polypeptide to the first polypeptide is at least about 9:1.

21 - 23 . (canceled)

24 . A method of preparing a cleaved two chain polypeptide comprising the amino acid sequence of SEQ ID NO: 3 or a polypeptide having at least about 80% sequence identity to SEQ ID NO: 3, wherein the method comprises expressing in an isolated cell:

a first polynucleotide encoding a polypeptide comprising the amino acid sequence of SEQ ID NO: 1 or a polypeptide having at least about 80% sequence identity to SEQ ID NO: 1 and

a second non-endogenous polynucleotide encoding a polypeptide comprising the amino acid sequence of SEQ ID NO: 2 or a polypeptide having at least about 80% sequence identity to SEQ ID NO: 2.

25 - 53 . (canceled)

Assignments (5)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 21, 2022
From: ALEXION PHARMACEUTICALS, INC.
To: ALEXION PHARMA INTERNATIONAL OPERATIONS UNLIMITED COMPANY
Reel/Frame 060799/0729 →
CHANGE OF NAME Recorded Jan 7, 2021
From: PORTOLA PHARMACEUTICALS, INC.
To: PORTOLA PHARMACEUTICALS, LLC
Reel/Frame 054920/0739 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 7, 2021
From: PORTOLA PHARMACEUTICALS, LLC
To: ALEXION PHARMACEUTICALS, INC.
Reel/Frame 054921/0131 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 7, 2021
From: ALEXION PHARMA INTERNATIONAL OPERATIONS UNLIMITED COMPANY
To: ALEXION PHARMACEUTICALS, INC.
Reel/Frame 054922/0857 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 4, 2017
From: LU, GENMIN; CONLEY, PAMELA B.; SINHA, UMA
To: PORTOLA PHARMACEUTICALS, INC.
Reel/Frame 041849/0008 →